Why Ocular Manifestations Like Iritis Are Linked to Ankylosing Spondylitis
Acute anterior uveitis (AAU/iritis) is the most common extra-articular manifestation of ankylosing spondylitis (AS), occurring in 30-40% of AS patients with prevalence approaching 60% in those with disease duration over 50 years, primarily driven by shared HLA-B27 genetic susceptibility and overlapping immune dysregulation pathways. 1
The Genetic Foundation: HLA-B27
The link between iritis and AS centers on HLA-B27 positivity, which is present in approximately 98% of AS patients with acute anterior uveitis 2. This genetic marker creates a shared immunologic vulnerability:
- HLA-B27 is the dominant genetic risk factor for both conditions, though additional genetic factors contribute 3
- Secondary genetic associations include ERAP1 (which shows differential effects on AAU versus AS alone), HLA-A*02:01, PSORS1C3, and TAP2 3
- Even in isolated acute anterior uveitis without systemic disease, HLA-B27 is present in 43% of cases 2
Immunologic Mechanisms
The pathophysiology involves shared inflammatory pathways between joint and ocular tissues:
Immune Cell Dysregulation
Recent single-cell profiling reveals distinct immune signatures in HLA-B27+ AS patients with AAU 4, 5:
- Monocyte activation with enhanced antigen processing and presentation pathways
- Myeloid cell activation is a key shared feature driving inflammation in both AS and AAU 5
- Cytotoxic T and NK cell enrichment specifically in AAU patients 5
- B-cell maturation and activation dysregulation more prominent in AS 5
Environmental and Systemic Factors
Beyond genetics, additional triggers include 6:
- Gram-negative bacterial infections
- Gut inflammation (explaining the IBD-spondyloarthritis-uveitis connection)
- Loss of immune homeostasis—the balance between pathogen elimination and self-tolerance 5
Clinical Presentation Pattern
AAU in AS typically presents as:
- Unilateral acute anterior uveitis
- High recurrence rate, sometimes alternating eyes 6
- Symptoms: eye pain, redness, photophobia 7
- Generally short-duration episodes responsive to topical glucocorticoids 7
Important Clinical Distinction
AAU associated with AS differs from uveitis in other spondyloarthropathies 6:
- AS and Reiter's syndrome: predominantly unilateral, acute, anterior
- Psoriatic arthritis and IBD-related: higher tendency toward bilateral, chronic, and posterior pole involvement
Risk Factors for Severe Uveitis in AS Patients
Factors associated with worse uveitis outcomes include 8:
- Smoking history
- Both axial and peripheral joint involvement (versus isolated disease)
- Active AS (ASDAS >2.1)
- HLA-B27 positivity
- Female sex
- Elevated CRP
- Bilateral ocular involvement
Clinical Implications
Why This Matters for Management
Education is paramount: HLA-B27+ patients with enthesitis-related arthritis or psoriatic arthritis must be educated about AAU warning signs to decrease treatment delay and prevent complications 7. This is considered standard of care despite very low quality evidence.
Treatment selection matters: When managing AS patients with recurrent uveitis, monoclonal antibody TNF inhibitors (adalimumab, infliximab) are preferred over other biologics 9, 10. Notably, etanercept may paradoxically worsen or trigger uveitis in AS patients 1.
Common Pitfall
Do not immediately escalate systemic therapy for isolated AAU episodes in otherwise well-controlled AS patients—treat first with topical glucocorticoids 7. Only frequent recurrent episodes warrant changing systemic therapy.
The connection between iritis and AS represents a shared genetic predisposition (HLA-B27) manifesting through overlapping immune dysregulation, particularly involving myeloid cell activation and antigen presentation pathways, with environmental factors and systemic inflammation serving as additional triggers.